Implementation Research on Efficacy of Pill-in-Hand Adherence Monitoring

Sarang Deo0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

试验速览

暂无简介。

•(1.) Patient has a residential address in the district of enrollment. Patient has a household address in the respective intervention district; patient is residing in the district at the time of enrollment, and patient plans to reside in the district for the six-month treatment duration period at the time of interview.
•(2.) Patient is initiated on FDCs upon notification: Patient is verified to have received their FDCs and is able to access regimen through the treatment duration.
•(3.) New, adult pulmonary case.
•(4.) Microbiologically confirmed case by any microbiological test (smear/culture/Xpert).
•(5.) DST for Rifampicin (Rif) / Isoniazid (INH) is negative.
•(6.) Patient has daily access to a mobile phone. Ownership of phone or daily access to a family memberâ??s phone for the treatment duration period, and able to maintain a minimum balance to make and receive calls.
•(7.) Has not been previously enrolled in the proposed intervention adherence monitoring methods. A history of prior TB treatment will be taken to ensure patient has not been previously exposed to adherence technologies.
•(8.) No other patient enrolled in the same household

•(1.) Patients prescribed treatment duration for longerâ?¯than 6 monthsâ?¯â??
•(2.) Patients whose follow-up is not feasible (i.e.,â?¯prisonâ?¯or other institutional settings prohibiting regularâ?¯access or communication with patient)â??

发起方

Sarang Deo